NCT06436274Active, not recruitingPhase 4
Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.
Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study.
Source: ClinicalTrials.gov · Last updated 12 Jan 2026
Brief summary (registry, in English)
The Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living with HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study is evaluating immediate or delayed single-dose nonavalent HPV vaccination among women living with HIV who received prior HPV vaccination.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 778 (actual)
- First submitted
- 24 May 2024
- Start date
- 14 Oct 2024
- Primary completion date
- Dec 2026
- Lead sponsor
- Massachusetts General Hospital
- Diseases
- HIV
- NCT number
- NCT06436274
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 778
- From 14 Oct 2024 to the primary completion date, Dec 2026
- 3 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Anyone with an allergy to vaccine components or yeast
Other
- Anyone with cervical abnormality on examination
Who the study is looking for
- Age 16 years and above on the day of signing the ICF
- Living with HIV with confirmed test results or clinic records
- History of receiving HPV vaccine
- Self-reported sexually active in the last six months
- Lives within the study area and willing to provide updated locator information over the course of the study
- Does not have an autoimmune, degenerative, or genetic disease
- Does not have known advanced HIV (as per stage IV WHO clinical staging criteria for HIV)
- No other Investigator-determined factor would limit participation in the trial
- Has not and is not enrolled in a monoclonal, investigational vaccine, or a large quantity blood draw study
- The participant has a cervix
Age in the registry: 16 years to - · Sex: Female · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Botswana Harvard Health Partnership Coordinator of this site? Confirm its status | Gaborone | Botswana | Unknown status |
| Ministry of Health and Center for Family Health Research Coordinator of this site? Confirm its status | Kigali | Rwanda | Unknown status |
| Wits RHI, University of the Witwatersrand Coordinator of this site? Confirm its status | Johannesburg | South Africa | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.